Compare Novo Nordisk A/S (NVO) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Shopify Inc. — how do they compare? Novo Nordisk A/S trades at $38.51 (market cap $165.31B), while Shopify Inc. trades at $168.43 (market cap $211.73B). The key difference: Shopify Inc. is the larger of the two by market cap, and Novo Nordisk A/S pays a 4.71% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Shopify Inc. for 78 Days on average.
| NVO | SHOP | |
|---|---|---|
Market Cap | $165.31B | $211.73B |
Volume | 11,432,838 | 7,146,651 |
Sector | Health | Technology |
52-Week High | $63.98 | $179.01 |
52-Week Low | $35.29 | $95.40 |
Typical Hold Time | 116 Days | 78 Days |
Enterprise Value | $179.56B | $206.96B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
SHOP trades at $168.69, up 1.66% today, with strong technical momentum as moving averages signal bullish sentiment. The company shows robust revenue growth from $5.6B in 2022 to $11.56B in 2025, though recent Q4 2025 EPS missed expectations. Analyst consensus remains bullish with 67% buy ratings and a $168.63 price target, while Shopify's AI innovations like Canvas and open AI agent access position it competitively against Amazon.
Outlook: Shopify's expanding merchant solutions and AI-driven commerce tools support growth, but high valuation multiples (P/E 111.19) and overbought RSI levels pose near-term risks. Investors should weigh strong fundamentals against premium pricing and competitive pressures in the e-commerce sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
